Orange Book product · Generic (ANDA)
DECITABINE
DECITABINE
At a glance
May 31, 2017
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 31, 2017
9 yr 2 mo ago
Today
Pharmaceutical detail
Active ingredient
DECITABINE
Strength
50MG/VIAL
Dosage form
INJECTABLE
Route
INTRAVENOUS
TE code
AP
Application
ANDA 204607
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of DECITABINE
- 2014DECITABINEBrand (NDA)
NDA 205582 · SUN PHARM
- 2006DACOGENBrand (NDA)
NDA 021790 · OTSUKA
- 2025DECITABINEGeneric (ANDA)
ANDA 217814 · RELIANCE LIFE SCI
- 2024DECITABINEGeneric (ANDA)
ANDA 215355 · HETERO LABS LTD VI
- 2022DECITABINEGeneric (ANDA)
ANDA 213472 · JIANGSU HANSOH PHARM
- 2021DECITABINEGeneric (ANDA)
ANDA 214486 · ZYDUS PHARMS
- 2021DECITABINEGeneric (ANDA)
ANDA 214569 · EUGIA PHARMA
- 2021DECITABINEGeneric (ANDA)
ANDA 212959 · MEITHEAL
- 2021DECITABINEGeneric (ANDA)
ANDA 212826 · QILU PHARM HAINAN
- 2020DECITABINEGeneric (ANDA)
ANDA 212117 · NIVAGEN PHARMS INC
- 2020DECITABINEGeneric (ANDA)
ANDA 205539 · GLAND
- 2019DECITABINEGeneric (ANDA)
ANDA 210984 · NOVAST LABS
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

